Donanemab Confirms: Clearing Plaques Slows Decline—By a Bit
GAP President John Dwyer speaks about GAP’s participation in the original Trailblazer trial, and our goals for TRAILBLAZER-ALZ 2. It has been clear for a while that anti-amyloid antibodies can sweep plaque from the brain, but until now the question of whether this slows cognitive decline has remained hotly contended. Despite some positive signals from […]